Riboflavin.

Pyridoxine 5-phosphate oxidase uses riboflavin as FMN to turn dietary B6 into pyridoxal 5-phosphate, the form enzymes actually use. Without enough riboflavin, B6 intake stays in a less usable form.

Methylenetetrahydrofolate reductase carries FAD made from riboflavin, and that enzyme produces the methyl folate used in homocysteine remethylation. Riboflavin status is a direct input to how well a folate dose moves through the methylation cycle.

Riboflavin supports the release of iron from ferritin stores and normal turnover of gut lining cells, both of which affect how efficiently iron is absorbed and moved. Low riboflavin status blunts the blood response to iron intake.

Kynurenine mono-oxygenase is an FAD enzyme in the pathway that converts tryptophan to niacin. Riboflavin sufficiency is what lets the body make part of its own niacin rather than relying on intake alone.

The alpha-keto acid dehydrogenase complexes use thiamine pyrophosphate at the first subunit and riboflavin-derived FAD at the third, so both are needed for one reaction to complete. A shortfall in either stalls the same step.

MTHFR, the enzyme that produces the methyl form of folate, is a flavoprotein that holds FAD made from riboflavin. Riboflavin status therefore sets how well the folate cycle turns over.

Methionine synthase reductase, which keeps the B12 cofactor on methionine synthase in its usable state, is FAD-dependent. Riboflavin sits upstream of the B12 and folate handoff.

Glutathione reductase is a flavoprotein that uses FAD to return oxidised glutathione to its reduced form. Without riboflavin the glutathione pool cannot be recharged.

Selenium-dependent glutathione peroxidase spends reduced glutathione, and the FAD-dependent reductase that riboflavin supports regenerates it. The two nutrients run consecutive steps of one cycle.

Carnitine carries fatty acids into the mitochondrion, where the acyl-CoA dehydrogenases and electron transfer flavoprotein that oxidise them all require FAD. Delivering substrate helps only if the flavin-dependent machinery is stocked.

Complex II and electron transfer flavoprotein both pass their electrons from FAD onto coenzyme Q. Riboflavin supplies the donor and CoQ10 is the acceptor in the same handoff.

Riboflavin has to be phosphorylated to FMN and then adenylylated to FAD, and both ATP-using steps require magnesium. Without magnesium the vitamin stays in its inactive form.

Pantothenic acid becomes coenzyme A, which carries the acyl groups that FAD-dependent dehydrogenases then oxidise. The two vitamins serve adjacent roles in the same beta-oxidation sequence.

Xanthine oxidoreductase carries both a molybdenum centre and FAD in the same protein, using the flavin to pass electrons out. Both trace nutrients are needed for that single enzyme to turn over.

Converting pyridoxine or pyridoxamine phosphate to pyridoxal 5'-phosphate is done by PNPO, which carries FMN as its cofactor. FMN comes from riboflavin through riboflavin kinase, so low riboflavin availability limits that activation step. Supplying the already-active P5P form bypasses the FMN-dependent step entirely. The cofactor relationship is textbook and needs no trial to state.

Methylenetetrahydrofolate reductase holds FAD as its cofactor, so folate cycling to the 5-methyl form depends on riboflavin status. The dependence is more pronounced in people carrying the MTHFR 677TT genotype, where the enzyme binds its FAD less tightly. That is a genotype, not a condition, and it explains why riboflavin adequacy shows up in folate and homocysteine work. The biochemistry is settled.

A portion of dietary tryptophan is converted to nicotinamide nucleotides through the kynurenine pathway. Kynurenine 3-monooxygenase in that pathway is a flavin-dependent enzyme, so riboflavin adequacy affects how efficiently the conversion runs. This links riboflavin status to the endogenous supply of niacin equivalents. It is a cofactor relationship, not a dosing claim.

FAD and FMN accept electrons that NADH and NADPH deliver, and the handoff runs through flavoproteins in the respiratory chain and in reductase systems. Neither carrier pool works independently of the other. That interdependence is the reason B-vitamin cofactors are usually formulated together rather than singly. It describes normal energy metabolism, not an added effect from stacking.

The E3 subunit shared by pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase and the branched-chain keto acid dehydrogenase complex is dihydrolipoamide dehydrogenase, which carries FAD. It regenerates the lipoamide arm on those complexes using NAD as the final acceptor. Riboflavin availability therefore sits directly upstream of lipoate recycling in those complexes. The relationship is standard biochemistry.

Recycling oxidised glutathione back to its reduced form is done by glutathione reductase, which holds FAD. N-acetylcysteine supplies the rate-limiting cysteine for making glutathione in the first place. One partner supplies the substrate and riboflavin supports the enzyme that keeps it in the useful state. The two act at different points of the same system.

Homocysteine is remethylated either by methionine synthase using 5-methyltetrahydrofolate, which depends on the FAD-requiring MTHFR upstream, or by betaine homocysteine methyltransferase using betaine directly. The betaine arm does not need riboflavin, so it runs in parallel rather than through the same bottleneck. Formulas often carry both to cover either route. The pathway map is established.

Choline dehydrogenase, itself a flavoprotein, oxidises choline toward betaine, which then donates a methyl group to homocysteine. That gives choline two connections to riboflavin, one as substrate for a flavoenzyme and one as an alternative to the FAD-dependent folate route. The relationship is a pathway description, not an effect size. Both nutrients are commonly present in the same B-complex.

Methionine is demethylated to homocysteine during methylation reactions and is regenerated by remethylation, one route of which runs through the FAD-dependent MTHFR step. Adding methionine raises flux into homocysteine, so the capacity of the remethylation arms matters more. Riboflavin adequacy is part of that capacity. This is pathway arithmetic, not a claimed benefit.

Riboflavin absorbs visible light and generates singlet oxygen and superoxide, which is why riboflavin-containing liquids are packed away from light. Ascorbic acid in the same solution is oxidised by those species and lost over shelf life. The interaction is a formulation and packaging matter rather than a physiological one. Solid formats and light-blocking packaging remove it.

Riboflavin is a substrate of the BCRP efflux transporter, and several dietary flavonoids including quercetin interact with that transporter in laboratory systems. That raises a plausible route by which large flavonoid doses could shift riboflavin distribution. It has been shown in transporter models rather than in people taking supplements. Read it as mechanistic.